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4-Nerolidylcatechol (1) is an isolated compound from Pothomorphe umbellata L. (Piperaceae) with pro-
mising antitumor cells properties. However it presents lability under light and room temperatures. Many
efforts have been directed towards discovering anticancer agents endowed with cytotoxic activities.
Here, we evaluated cytotoxic effects of 4-NRC analogues (LQFMs 2–6) and the cell death pathways in-
duced by these compounds in multidrug-resistant K562 cells. Compounds (2–6) exhibited cytotoxic
activities in a concentration-dependent manner against leukaemic cells, specially the compounds (3) and
(5). Additionally, compounds (1), (3) and (5) promoted marked alterations on the cell morphology, in-
cluding nuclear changes as demonstrated by Hoescht 33342 staining. Moreover, these compounds pro-
moted apoptosis induction in K562 cells by phosphatidylserine exposure, increase of sub-G1 cells and
modulation of the caspases-3/7, -8 and -9 activation. In addition, the pancaspase inhibitor z-VAD-fmk
partially reduced the apoptosis induced by the compounds (1) and (5)-induced, suggesting caspase-
dependent and caspase-independent cell death pathways. Compounds (1) and (5) also modiﬁed the cell
cycle progression by G0/G1 and S arrest, respectively. Furthermore, compounds (1), (3) and (5) promoted
mitochondrial dysfunction associated to accumulation of cytosolic cytochrome c and modulated the NF-
ĸB activation. In addition, unlike their analogues, 4-NRC (1) also promoted a signiﬁcant cyclin D1 in-
hibition. Together, these data suggest that the mechanism of cell death of 4-NRC and its analogues
(3) and (5) occurs by apoptosis through mitochondrial mechanisms. Considering that LQFMs are bio-
compatible synthetic analogues produced by molecular simpliﬁcation of (1) without the chiral centre,
which is associated with the instability found in compound (1), we suggest that these compounds are
promising candidates for further pre-clinical studies.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
4-Nerolidylcatechol (4-NRC) (1) is a phenolic compound iso-
lated from Brazilian plants such as Pothomorphe umbellata L. (Pi-
peraceae) (Noriega et al., 2005; Viana et al., 2004). Several biolo-
gical properties has been attributed to this compound, including
antioxidant (Lopes et al., 2013), chemopreventive (Valadares et al.,
2007), antitumor (Sacoman et al., 2008), cytotoxic (Lopes et al., 2013;
Mongelli et al., 1999), antimalarial (Bagatela et al., 2013) and anti-
fungal (Rodrigues et al., 2012) effects. Recently, it was demonstrated
that 4-NRC-induced apoptosis in human chronic myeloid leukaemiaiversidade Federal de Goiás,
ário, Goiânia CEP: 74605.170,
aladares).
y.K562 cells by mitochondrial-dependent pathways (Benﬁca et al.,
submitted). Although these promising biological effects demon-
strated, this natural compound presents lability under light and room
temperatures which is a limiting factor for it uses.
Apoptosis is a fundamental process that maintains cell home-
ostasis by controlling physiological processes in healthy in-
dividuals by the balance of cell proliferation and death (Chen and
Lai, 2009; Elmore, 2007). When pro-death proteins are activated,
apoptosis occurs; on the other hand pro-survival molecules drive
to pathological conditions, such as cancer (Mohammad et al., in
press). Considering that most tumours have heterogeneous sub-
populations of immortalized cells, anticancer agents showing dif-
ferent mechanisms of actions able to arrest these cells has been
required (Mohammad et al., in press). In this context, discovery
and/or synthesis of compounds that can induce apoptosis in tu-
mour cells have been encouraged (Cragg and Newman, 2013; Chen
and Lai, 2009; Ghobrial et al., 2005).
Fig. 1. Chemical structure of 4-nerolidylcatechol (4-NRC) (1) and its analogues (2–6).
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6) were designed using a molecular simpliﬁcation strategy to
evaluate their cytotoxic effects and their ability to induce apop-
tosis against leukaemic cells (Fig. 1). The molecular simpliﬁcations
realized in the structure of the lead compound (1) consisted of
retention of aromatic ring or its replacement with heteroaromatic
ring and maintenance of the lateral chain without the chiral centre
(Cunha et al., 2013).
Contributing to development of new therapeutic agents, this
study evaluated cytotoxic effects of 4-NRC analogues as well as
assessment of cell death pathways induced by these compounds in
multidrug-resistant K562 cells.2. Materials and methods
2.1. Reagents
RPMI 1640 medium, streptomycin, penicillin G and fetal bovine
serum (FBS), trypan blue, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyl tetrazolium bromide (MTT), propidium iodide (PI), sodium
bicarbonate, rhodamine 123, dichloro-dihydro-ﬂuorescein diace-
tate (DCFH-DA) and RNAse were obtained from Sigma (St. Louis,
MO, USA). The primary antibodies (cytochrome c, cyclin D1, NF-
κB) were obtained from Santa Cruz Biotechnology (CA, USA),
whereas an Annexin V Apoptosis Detection Kit FITC and a Caspa-
Tag™ Caspase-3,-7, -8 and -9 In Situ Assay kit were acquired from
eBiosciences (San Diego, CA, USA) and Millipore™ (Temecula, CA,
USA), respectively. Ethanol, methanol and dimeltilsulfoxide
(DMSO) were acquired from Merck (Darmstad, Germany) whereas
tween 20 was obtained from Vetec (Rio de Janeiro, RJ, Brazil). BD
Cytoﬁx/Cytoperm™ solution was acquired from BD Biosciences
(San Jose, CA, USA) while Hoechst 33342 and MitoTrackers Red
CMXRos probe were purchased from Invitrogen (Grand Island, NY,
USA). Pancaspase inhibitor z-VAD-fmk was acquired from R&D
Systems (Mineapolis, MN, USA).2.2. Compounds test
The 4-NRC was extracted from P. umbellata according to Re-
zende and Barros (2004) while its analogues (2–6) were synthe-
sized and characterised according to Cunha et al. (2013). Purity of
the compounds was determined as above 98%. For the assays,
4-NRC and the analogues (2–6) were dissolved in ethanol and
DMSO and stored at 20 °C and 4 °C, respectively.2.3. Cell lines
The human K562 cell line was obtained from Rio de Janeiro Cell
Bank (Federal University of Rio de Janeiro, Rio de Janeiro, Brazil)
and cultured in suspensions in RPMI 1640 medium supplemented
with inactivated fetal bovine serum (FBS) (10%), penicillin (100 U/
ml) and streptomycin (100 mg/ml) in a humidiﬁed atmosphere at
37 °C in 5% CO2.
2.4. MTT assay
This assay was performed using 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide (MTT) reduction test as pre-
viously described by Mosmann (1983) and modiﬁed by Mota et al.
(2012). Brieﬂy, the cells (1106 cells/ml) were plated in triplicate
in 96-well plates in RPMI 1640 medium supplemented with 10%
FBS and treated with eight concentrations of the compounds (1–
6). After 24, 48 or 72 h of incubation, 10 mL of MTT (5 mg/ml) were
added to each well and the plates incubated for additional 3 h. The
blue MTT forms a precipitate, which it was then dissolved in
DMSO. The absorbance was measured using a spectrophotometer
(Thermo Scientiﬁc Multiskans Spectrum, Boston, MA, USA) at
550 nm. Cell viability was expressed as a percentage of the control
and IC50 values (concentration that inhibited cell growth in 50%
compared to untreated group) were obtained. For the subsequent
assays, the 4-NRC (1) and its analogues that showed lower IC50
values, LQFM002 (3) and LQFM015 (5), were used.
2.5. Phosphatidylserine (PS) externalization analysis
The K562 cells (1106 cells/ml) were treated with the com-
pounds (1), (3) or (5) for 24, 48 or 72 h and PS exposure performed
by a ﬂow cytometer using an Annexin V Apoptosis Detection Kit
FITC (eBiosciences, San Diego, CA, USA) in accordance with the
manufacturer’s instructions. Four cell populations were identiﬁed:
necrotic cells in the upper-left quadrant (high PI and low FITC
signals, A/PIþ); early apoptotic cells in the lower-right quadrant
(low PI and high FITC signals, Aþ/PI); late apoptotic cells in the
upper-right quadrant (Aþ/PIþ); and viable cells in the lower-left
quadrant (low PI and FITC signals, A/PI).
2.6. Cell morphology
K562 cells were treated with the compounds (1) (24.5 mM), (3)
(140 mM) or (5) (135 mM) for 24 h and the morphologic changes
were analysed by a light microscope (DM 2000, Leica micro-
systems, USA). The images were taken using a 40 objective
ampliﬁed with 3.6 zoom (Canon Powershot S80 camera). After
Table 1
Cytotoxic activity of 4-NRC (1) and its analogues (2–6) in multidrug-resistant K562
cells evaluated by the MTT assay.
Compound IC50values (lM)
24 h 48 h 72 h
4-NRC (1) 24.5 21.2 26.4
LQFM001 (2) 607 507 432
LQFM002 (3) 140 105 90.7
LQFM014 (4) 720 484 237
LQFM015 (5) 135 64.7 57.5
LQFM016 (6) 507 232 63.8
Data are presented as IC50 values (mM) from three independent experiments, per-
formed in six replicates, after 24, 48 and 72 h of treatment.
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with DNA binding dye Hoechst 33342 (Mota et al., 2012) to eval-
uate nuclear changes triggered by the compounds (1), (3) and (5)
using a ﬂuorescence microscope (DMI 4000 B Leica Microsystems,
Bannockburn, IL, USA) (40 objective) coupled to the software
LAS-AF ﬁlter A4 (blue colour).
2.7. Cell cycle analysis and apoptosis induction
K562 cells (1106 cells/ml) were treated with compounds (1),
(3) or (5) for 24 h and then ﬁxed with 70% ice-cold ethanol for
24 h. Then, the cells were washed twice with PBS and incubated
with 300 mL PBS solution containing RNAse (200 mg/ml) and pro-
pidium iodide (PI) (50 mg/ml) at room temperature, in the dark, for
1 h. The DNA content was detected using a in a FACSCanto II ﬂow
cytometer (Becton Dickinson, CA, USA) using the FACSDiva soft-
ware. The sub-diploid DNA cells accumulated in sub-G1 position
were identiﬁed as apoptotic and the cell percentages in each phase
(G0/G1, S or G2/M) of the cell cycle were determined. In parallel,
another cell groups were also pre-treated with the pancaspase
inhibitor z-VAD-fmk (20 mM) for 30 min after treatment with the
compounds (1), (3) or (5). Moreover, determination of the caspases
activities was assessed by a ﬂow cytometer using the CaspaTag™
Caspase-3/7, -8 and -9 In Situ Assay kit (Millipore™, Temecula, CA,
USA) in accordance with the manufacturer’s instructions.
2.8. Nuclear changes assessment
K562 cells treated with the compounds (1) (24.5 mM), (3)
(140 mM) or (5) (135 mM) for 24 h were seeded on BD cell-tak™-
coated coverslips and ﬁxed with methanol. Then, the cells were
permeabilized in PBS-tween 20 solution and incubated with
Hoescht 33342 (0.5 μg/ml) for 20 min at room temperature, in the
dark. After, cell nuclei were evaluated using ﬂuorescence micro-
scope (DMI 4000 B Leica Microsystems, Bannockburn, IL, USA)
coupled to the software LAS-AF.
2.9. Mitochondrial function analysis
2.9.1. Evaluation of mitochondrial transmembrane potential (ΔΨm)
The K562 cells (1106 cells/ml) were treated with compounds
(1), (3) or (5) and incubated for 24 h. Afterwards, the cells were
washed with PBS and stained with rhodamine 123 (1 mg/ml) in the
dark for 1 h at 37 °C. The cells were analysed by a ﬂow cytometer
to determine the mitochondrial membrane depolarization.
2.9.2. Evaluation of mitochondrial functionality
Additionally, mitochondria functionality was evaluated using
MitoTracker Red. After treatment, K562 cells (1106 cells/ml)
were washed twice with PBS and incubated with MitoTrackers
Red CMXRos (10 nM) in PBS for 15 min at 37 °C in 5% CO2. Then,
the cells were washed twice, resuspended in 0.2 mL of PBS and
analysis was performed in a ﬂow cytometer.
2.9.3. Cytochrome c release from mitochondria to cell cytosol
After treatment, K562 cells (1106 cells/ml) were washed
twice with PBS–BSA and posteriorly ﬁxed and permeabilized with
BD Cytoﬁx/Cytoperm™ solution for 20 min at 4 °C. Then, the cells
were washed with PBS–Tween 20 solution and incubated for
20 min with a cytochrome c antibody followed of analysis in a ﬂow
cytometer.
2.10. . Cyclin D1 and NF-κB expression
K562 cells treated with the compounds (1), (3) or (5) for 24 h
were ﬁxed and permeabilized as previously described, incubatedfor 20 min with cyclin D1 or NF-κB antibodies and analysed in a
ﬂow cytometer.
2.11. 1 Statistical analysis
The assays were carried out by three independent experiments.
The cytotoxicity results, expressed as the mean7SD of six re-
plicates, were transformed in percentages, compared to control
and IC50 values were obtained. For ﬂow cytometry analysis, 10,000
events were collected per sample of each assay with a FACSCanto II
ﬂow cytometer using the FACSDiva software. The inter group
variation was measured by the Student's t-test or one-way or two-
way Analysis of Variance (ANOVA) followed by Bonferroni test
using GraphPad Prism version 5.01 software for windows (San
Diego, CA, USA). Statistical signiﬁcance was considered when
Po0.05.3. Results
3.1. Cell viability analysis
K562 leukaemic cells were treated with the compounds (1–6)
for 24, 48 or 72 h and the cytotoxicity was carried out using MTT
assay. The proliferation of the K562 cells was inhibited by 4-NRC
and its analogues in a concentration and time dependent-manner.
IC50 values obtained are shown in the Table 1. In relation to 4-NRC
(1), analogues (3) and (5) showed the lower IC50 values. Thus,
these compounds were used in the subsequent mechanistic assays.
The effects of compounds (1–6) were also investigated on Jurkat
leukaemic and Ehrlich ascites tumour (EAT) cells showing similar
results (data not shown). Considering that K562 cells are a drug
resistant cell line and was sensitive to cytotoxic effects of the
compounds (1), (3) and (5), this cell line was chosen for additional
studies.
3.2. PS exposure induced by 4-NRC (1) and its analogues (3) and (5)
Loss of plasma membrane asymmetry by PS exposure in K562
cells treated with 4-NRC (1) and its analogues (3) and (5) was
evaluated by Annexin V-FITC/PI double-staining (Fig. 2A and B). It
was veriﬁed that all compounds promoted a reduction on cell
viability (A/PI viable cells) in a time dependent-manner, being
the lowest values found at 72 h of treatment (Po0.0001). More-
over, apoptotic cell death (Aþ/PI and Aþ/PIþ cells) was ob-
served, especially in the same time for late apoptotic cells (Aþ/
PIþ) (Po0.0001). A secondary necrosis (A/PIþ cells) was also
obtained in a lower frequency. Thus, our data suggest an apoptotic
death process triggered by the compounds (1), (3) and (5). Among
the compounds, the analogue LQFM002 (3) was more effective in
Fig. 2. Phosphatidylserine (PS) externalization analysis in K562 cells treated with 4-NRC (1) and its analogues (3) and (5). (A) Representative proﬁles of PS externalizationof
K562 cells treated with 4-NRC (1) and its analogues (3) and (5) for 24, 48 and 72 h. The concentrations used were the IC50 values obtained in the MTT assay. (B) Percentage of
viable (A/PI), early apoptotic (Aþ/PI), late apoptotic (Aþ/PIþ) and necrotic (A-/PIþ) cells in 24, 48 and 72 h of treatment with the compounds (1), (3) and (5).
(*Po0.05, **Po0.001 and ***Po0.0001 vs. control).
A.P. Cortez et al. / European Journal of Pharmacology 765 (2015) 517–524520induce apoptotic cell death in K562 cells measured by the increase
of PS exposure.
3.3. Effects of 4-NRC (1) and its analogues (3) and (5) on cell
morphology
Treatment of K562 cells with 4-NRC (1) and its analogues (3)
and (5) caused marked alterations on the cell morphology, such as
cell size, shape and plasma membrane changes, when compared
with control (Fig. 3A). In addition, Hoescht 33342 staining de-
monstrated nuclei broken into fragments with consequently low
ﬂuorescence as well as chromatin condensation and shrinking
nuclei, constrasting with control cells (Fig. 3B). Again, these ﬁnd-
ings are suggestive features of apoptotic cell death.
3.4. Effects of 4-NRC (1) and its analogues (3) and (5) in cell cycle
progression and apoptosis induction
Representative proﬁles of K562 cells treated for 24 h with
4-NRC (1) and its analogues (3) and (5) are shown in Figure 4 A. As
expected, 4-NRC (1) promoted a signiﬁcant increase of cells in G0/G1 (Po0.001) and reduction in the S and G2/M phases. The ana-
logue (5) induced a signiﬁcant S phase accumulation (Po0.05)
and a G2/M phase decrease (Po0.001) of K562 cells. Analogue (3)
did not promote signiﬁcant changes in the cell cycle when com-
pared to control. Thus, the compounds (1) and (5) were able to
modify the cell cycle progression (Fig. 4B) by G0/G1 and S arrest,
respectively. In addition, all compounds induced a signiﬁcant in-
crease of sub-G1 apoptotic cells (Po0.0001) (Fig. 4C). In relation
to caspases activation, the results revealed a modulatory effect of
caspases-3/7, -8 and -9 triggered by the compounds (1), (3) and (5)
in K562 cells (data not shown). To clarify the effects of 4-NRC and
its analogues on cell death, especially involving caspases activa-
tion, we co-treated K562 cells with pancaspase inhibitor z-VAD-
fmk (Fig. 4C). When the cells were co-treated with the pancaspase
inhibitor z-VAD-fmk, apoptosis induced by 4-NRC (1) and analo-
gue (5) was partially blocked, demonstrating that these com-
pounds possibly activate both caspase-dependent and caspase-
independent cell death pathways. In relation to analogue (3), the
apoptotic process reached the levels of control by co-treatment
with z-VAD-fmk, suggesting that this compound probably triggers
a cell death exclusively caspase-dependent.
Fig. 3. Effects of 4-NRC (1) and its analogues (3) and (5) on the cell morphology of K562 cells. The cells were treated with 4-NRC (1) (24.5 mM) and its analogues (3) (140 mM)
and (5) (135 mM) for 24 h, placed on glass slides and analysed by light and ﬂuorescence microscope using a 40 objective. The images are representative of three in-
dependent assays. Bars: 10 mm. (A) Aspect of K562 cell culture with and without treatment. (B) Hoescht 33342 staining presenting nuclei broken into fragments and
consequently with low ﬂuorescence as well as chromatin condensation and shrinking nuclei in treated cells, contrasting with control cells.
A.P. Cortez et al. / European Journal of Pharmacology 765 (2015) 517–524 5213.5. Mitochondrial dysfunction promoted by 4-NRC (1) and its
analogues (3) and (5)
Mitochondrial assessment showed that the 4-NRC (1) and its
analogues, (3) and (5) promoted a loss of the ΔΨm of 49, 9.3% and
3.3%, respectively. Similar results were obtained with theFig. 4. Sub-G1 and cell cycle analysis in K562 cells treated with 4-NRC (1) and its analo
cells treated with 4-NRC (1) (24.5 mM) and its analogues (3) (140 mM) and (5) (135 mM)
(C) Percentage of sub-G1 apoptotic cells after K562 cells were treated only with the co
(20 mM). (*Po0.05, **Po0.001 and ***Po0.0001 vs. control; ##Po0.001 and ###Po0.0MitoTracker Red staining (Fig. 5A and B) conﬁrming the effects of
these compounds on the mitochondrial functionality. Moreover it
was demonstrated a signiﬁcant accumulation of cytosolic cyto-
chrome c induced by 4-NRC (1) (Po0.05) and its analogues (3)
(Po0.0001) and (5) (Po0.0001) in contrast to untreated cells
(Fig. 6C).gues (3) and (5). (A) Representative histograms of the analysis of cell cycle in K562
for 24 h. (B) Percentage of cells in the G0/G1, S and G2/M phases of the cell cycle.
mpounds or co-treated with the compounds and pancaspase inhibitor z-VAD-fmk
001 vs. LQFM002 (3)þz-VAD-fmk and LQFM015 (5)þz-VAD-fmk, respectively).
Fig. 5. Mitochondrial function analysis of K562 cells treated with 4-NRC (1) and its analogues (3) and (5). The K562 cells were treated with 4-NRC (1) (24.5 mM) and its
analogues (3) (140 mM) and (5) (135 mM) for 24 h and mitochondrial function was analysed as following: (A) mitochondrial transmembrane potential (ΔΨm) changes by
rhodamine 123 staining, (B) Mitotracker Red staining and (C) cytochrome c release from mitochondria to cell cytosol. (*Po0.05 and ***Po0.0001 vs. control).
Fig. 6. Involvement of cyclin D1 and NF-κB in the in the apoptosis induced by 4-NRC (1) and its analogues (3) and (5). K562 cells treated with 4-NRC (1) (24.5 mM) and its
analogues (3) (140 mM) and (5) (135 mM) for 24 h and cyclin D1 and NF-κB expressions were evaluated by ﬂow cytometer. (***Po0.0001 vs. control).
A.P. Cortez et al. / European Journal of Pharmacology 765 (2015) 517–5245223.6. Involvement of cyclin D1 and NF-κB in the in the apoptosis in-
duced by 4-NRC (1) and its analogues (3) and (5)
The role of signaling molecules cyclin D1 and NF-ĸB in the
apoptosis induced by 4-NRC (1) and its analogues (3) and (5) in
K562 cells were investigated. These compounds were signiﬁcantly
able to modulate the NF-ĸB activation by inhibition of about 10%
(Po0.0001) (Fig. 6A). In addition, unlike their analogues, 4-NRC
(1) also promoted a signiﬁcant cyclin D1 inhibition (Po0.0001),
when compared to untreated cells (Fig. 6B).4. Discussion
Previously, we demonstrated that the synthetic compounds
LQFMs (2–6), specially the compound (5), have an antioxidant
proﬁle similar to the 4-NRC (1) lead compound, and these com-
pounds appear to be highly biocompatible in contrast with the
4-NRC (Cunha et al., 2013). Another advantage of the LQFMs
compounds in relation to 4-NRC is associated to stability, since
compound (1) has a chiral centre which is related to its lability
under light and room temperatures (Pinto et al., 2009).
A.P. Cortez et al. / European Journal of Pharmacology 765 (2015) 517–524 523In the present study, we investigated the cytotoxic activity and
mechanisms of cell death of LQFMs (2–6) and compound (1) in
K562 cells. The data presented here added more information about
the biological activities of LQFMs compounds and elucidated, at
least in part, the mechanism of cells death induced by the lead
compound and its derivatives. Our results showed that the com-
pounds (1–6) have signiﬁcant anti-proliferative activity against the
leukaemic cells, in special (3) (pyrazole analogue) and (5) (phenol
analogue) which were similar to compound (1).
Pinto et al. (2009) evaluated the cytotoxic effect of compound (1)
and its semi-synthetic diacetyl derivative and showed that the dia-
cetyl derivative had an increased cytotoxic activity against the HL-60
and CEM human leukaemic cell lines compared to compound (1). It
was also observed that mono-O-methyl ether derivatives of com-
pound (1) had cytotoxic effects in the human colon carcinoma cell
line HCT-8 (8.38–28.73 mg/ml), central nervous system cell line SF-
295 (10.76–38.82 mg/ml), human myeloblastic leukaemia cell line HL-
60 (4.74–30.8 mg/ml) and melanoma cell line MDA-MB-435 (15.92–
21.67 mg/ml) (Pinto et al., 2009). Our study demonstrated similar
results when evaluating the cytotoxic effect in K562 cells, a multi-
drug resistant cell, after treatment with compounds (1), (3) and (5).
In contrast, Ramos et al. (2011) produced a derivative of compound
(1) using the biotransformation of Heraclides brasiliensis (Lepi-
doptera: Papilionidae) larvae. This derivative showed a reduction of
cytotoxicity when compared to the lead compound (1). As expected,
the biotransformation process reduced the toxicity of the lead com-
pound (IC50 of 8.0 and 41000 μg/ml).
Yang et al. (2007) suggest that the cytotoxic activity of ca-
techols is related to the catechol-derived semiquinone radicals,
which can, in some cases, still donate a H-atom to generate qui-
none, producing a superoxide anion radical that causes oxidative
stress. Zapor (2004) evaluated the cytotoxic effects of 5 phenol
derivatives (phenol, catechol, resorcinol, hydroquinone and
phloroglucinol) in the mouse 3T3 ﬁbroblast cell line and suggested
that the cytotoxic activity of phenolic compounds probably de-
pends on the number of –OH groups and their position in the
aromatic ring. In addition, Cornwell et al. (1998) demonstrated
that tocopherols and their quinones are highly cytotoxic agents
against acute lymphoblastic leukaemia cell lines. Toton et al.
(2013) also showed the cytotoxic effects of pyrazoles compounds
using HT29 colon cancer. In this respect, the synthetic pyrazolic
compound (3) showed important cytotoxic effects. This compound
has a modiﬁcation on the lateral chain of the pyrazole group
without the chiral centre.
The hallmark genetic abnormality of chronic myelogenous leu-
kaemia (CML) is the’Philadelphia chromosome’, small chromosome
resultant of a t(9;22)(q34;q11) translocation, which resulted the
chimeric gene BCR-ABL1 (Chen et al. 2010; Ren, 2005). Imatinib, a
potent inhibitor of the oncogenic tyrosine kinase BCR-ABL, has
shown remarkable clinical activity in patients with CML. However,
resistance to imatinib drove to development of the second and third
tyrosine kinase inhibitors (Ren, 2005; Tanaka and Kimura, 2008).
Thus, alternative drugs have been developed to circumvent this re-
sistance (De Martino et al. 2011; Lamontanara et al. 2013; Schenone
et al. 2011). In this respect, the compounds (1), (3) and (5) induced a
signiﬁcant accumulation of cell population in sub-G1 phase sug-
gesting that these compounds were able to promote apoptosis in
K562 cells, a multiple drug resistance cell line. Similarly, Brohem
et al. (2009) showed that compound (1) promoted high percentage
of fragmented DNA in tumoral cells. In this context, we demonstrated
here by analyses of phosphatidylserine externalization and involve-
ment of caspases that the treatment of K562 cells with the com-
pounds (1), (3) and (5) promoted cell death by apoptosis.
NF-κB plays a central role in control multiple cellular processes
in cancer including transformation, proliferation, invasion, che-
moresistance and radioresistance. This factor is constitutivelyactive in most tumour cells and its suppression inhibits the growth
of tumour cells (Chaturvedi et al., 2011). In CML, the fusion protein
BCR-ABL activates NF-κB-dependent transcription by causing nu-
clear translocation of NF-kB as well as by increasing the transac-
tivation function of the RelA/p65 subunit of NF-κB (Chaturvedi
et al., 2011; Reuther et al., 1998). Many genes are modulated by NF-
κB transcription factor including cyclin D1, a key regulator of G1
checkpoint control (Aggarwal, 2004; Hinz et al., 1999; Kim et al.,
2006). In our study, the treatment of K562 cells with the com-
pounds (1), (3) or (5) decreased NF-κB expression. In addition,
cyclin D1 expression was decreased with compound (1) treatment.
Mitochondria are organelles highly involved in apoptosis pro-
cess. Its integrity is critical for cell survival, thus the loss of
membrane potential and release factors such as cytochrome c
triggers caspase activation and leads the cell to death (Phillips
et al., 2007; Yadav and Chandra, 2014). Cytochrome c release was
observed after treatment with compounds (1), (3) and (5). The
compounds (3) and (5) showed a more pronounced effect on cy-
tochrome c release compared to 4-NRC. However, reactive oxygen
species analysis of treated cells did not revealed a signiﬁcant dif-
ference in reactive oxygen species induction in comparison to the
untreated cells after 3, 6 and 24 h of treatment (data not shown).
Furthermore, membrane potential analysis revealed a decreased
after treatment, especially with the compounds (1) and (3), while
the compound (5) showed a modest decrease.
In conclusion, our results suggest that compounds (3) and (5)
have cytotoxic activities against the multidrug-resistant K562 cells
similar to compound (1). The mechanism of cell death induced by
these compounds occurs by apoptosis through mitochondrial
mechanisms. Considering that LQFMs are biocompatible synthetic
analogues produced by molecular simpliﬁcation of (1) without the
chiral centre, which is associated with the instability found in
compound (1), we suggest that these compounds are promising
candidates for further pre-clinical studies.Acknowledgements
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